For the Inventor, By the Inventor

Enter assignee name

Zwijnaarde, Belgium

Vlaams Interuniversitair Instituut Voor Biotechnologie Vzw

USPTO Granted Patents = 44

CIPO Patents = 6

EPO Patents = 7

Forward Citations = 166

Loading Chart...

Loading Chart...

76 inventors (with patents filed for the assignee):

Peter Carmeliet (11 out of 21 patents)

Désiré Collen (8 out of 10 patents)

Jan Tavernier (5 out of 62 patents)

4. Rudi Beyaert (5 out of 9 patents)

5. Sven Eyckerman (4 out of 13 patents)

6. Walter C Fiers (4 out of 32 patents)

7. Patrick De Baetselier (3 out of 11 patents)

8. Jean-Marie Stassen (3 out of 6 patents)

9. Joel S Vandekerckhove (3 out of 8 patents)

10. Annick Verhee (3 out of 3 patents)

11. Frans Van Roy (3 out of 3 patents)

12. Gabriel Iturriaga De La Fuente (2 out of 3 patents)

13. Johan M Thevelein (2 out of 3 patents)

14. Patrick Van Dijck (2 out of 4 patents)

15. Karen Heyninck (2 out of 3 patents)

Core Competencies:

Anti-Angiogenic Therapy

Genetic Modification

Heavy Chain Antibodies

Protein-Protein Interaction Trap

Stem Cell Recruitment

Aging Biomarkers

VEGF Treatment

Amyotrophic Lateral Sclerosis

Tumor Progression Control

Placental Growth Factor

Hypoxia Inducible Factor

Cytokine-Producing Strain

44 patents: Sort by Forward Citations

1. 9085617 - Anti-angiogenic therapy (2015-07-21),

2. 8796505 - Specific genetic modification of the activity of trehalose-6-phosphate synthase and expression in a homologous or heterologous environment (2014-08-05),

3. 8758748 - Anti-angiogenic therapy (2014-06-24),

4. 8097251 - Functional heavy chain antibodies, fragments thereof, library thereof and methods of production thereof (2012-01-17),

5. 8048986 - Reversed mammalian protein-protein interaction trap (2011-11-01),

6. 8003757 - Receptor-based interaction trap (2011-08-23),

7. 8003096 - Means and methods for the recruitment and identification of stem cells (2011-08-23),

8. 7993822 - Aging biomarker (2011-08-09),

9. 7888322 - Use of VEGF and homologues to treat neuron disorders (2011-02-15),

10. 7875704 - Anti-PLGF antibody (2011-01-25),

11. 7863246 - Treatment of amyotrophic lateral sclerosis (2011-01-04),

12. 7855270 - Receptor-based interaction trap (2010-12-21),

13. 7807809 - Molecular characterization of chromosome translocation t(11;18)(q21;q21) and its correlation to carcinogenesis (2010-10-05),

14. 7781646 - Specific genetic modification of the activity of trehalose-6-phosphate synthase and expression in a homologous or heterologous environment (2010-08-24),

15. 7687463 - Treatment of amyotrophic lateral sclerosis (2010-03-30),

Vlaams Interuniversitair Instituut voor Biotechnologie vzw (VIB) is a leading life sciences research institute in Belgium. VIB performs groundbreaking research in the field of biotechnology and seeks to translate its discoveries into innovative applications in the healthcare, agriculture, and industrial sectors. With partnerships between five Flemish universities, VIB fosters collaboration and knowledge exchange among scientists, ensuring the development of cutting-edge biotechnological solutions. VIB's mission is to advance the understanding of life at a molecular level and contribute to improving the quality of life for all.

This text is generated by artificial intelligence and may not be accurate.

Company Badge

USPTO Data Jan 1 1976 - Dec 30 2025

44 Patents

#3 in Zwijnaarde

#94 in Belgium

#15,296 in the World

Zwijnaarde, Belgium

Vlaams Interuniversitair Instituut Voor Biotechnologie Vzw

Forward Citations = 166

76 inventors:

Peter Carmeliet (11 out of 21 patents)

Désiré Collen (8 out of 10 patents)

Jan Tavernier (5 out of 62 patents)

4. Rudi Beyaert (5 out of 9 patents)

5. Sven Eyckerman (4 out of 13 patents)

Please report any incorrect information to support@idiyas.com

Loading…